Hormonal
GLP-1 receptor agonists (GLP-1RAs) provide superior glycemic control compared to DPP-4 inhibitors in type 2 diabetes, primarily due to higher pharmacological concentrations of GLP-1 and distinct tissue distribution patterns.
If oral diabetes medications are not controlling your blood sugar well enough, switching to a GLP-1 injection (like liraglutide or semaglutide) is likely to lower your A1c more effectively than switching to a DPP-4 inhibitor pill (like sitagliptin). GLP-1 injections also tend to promote weight loss, whereas DPP-4 inhibitors are generally weight-neutral. The trade-off is that GLP-1s require injections and may cause initial nausea.
These trials clearly indicate that GLP-1RAs are more effective at controlling glycaemia than are DPP-4 inhibitors, potentially because of the differences in GLP-1/GLP-1RA concentrations.
Why this rating
Based on multiple head-to-head clinical trials cited (e.g., liraglutide vs sitagliptin, exenatide vs sitagliptin) showing statistically significant differences.
Source
Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors
Michael A. Nauck · Diabetes Obesity and Metabolism · 2015
DOI 10.1111/dom.12591
More from this paper
- GLP-1 receptor agonists and DPP-4 inhibitors both have a low risk of hypoglycemia when used as monotherapy due to their glucose-dependent mechanism of action.Strong
- GLP-1 receptor agonists promote weight loss, whereas DPP-4 inhibitors are generally weight-neutral, making GLP-1RAs more suitable for obese T2D patients.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →